Price Comparisons

Price Comparisons

Compare UK weight loss injection prices by provider, understand what affects the cost, and find the best route for Mounjaro or Wegovy.

Whether you are budgeting for a weight-loss injection course or comparing options on price specifically, this is the price comparisons hub for weight-loss injections in the UK. The focus is the price-side comparison: dose-by-dose, medicine-by-medicine, NHS vs private, and how to read provider pricing. For broader medicine comparisons (efficacy, side effects, mechanism), see our medication comparisons hub. LetsLoseWeight is an independent comparison site; we do not prescribe medication, and our pricing data is gathered independently from public provider listings.

At-a-glance: typical UK private prices

As a rough range at the time of this guide's last review:

Medicine Starter doses Mid doses Maintenance / max dose
Mounjaro (tirzepatide) £130–£190 (2.5mg) £160–£260 (5–10mg) £200–£300+ (12.5–15mg)
Wegovy (semaglutide) £130–£170 (0.25–0.5mg) £180–£240 (1–1.7mg) £230–£300+ (2.4mg)
Retatrutide Not licensed in UK — no legitimate price

For provider-by-provider live data:

For lowest-price options:

Mounjaro vs Wegovy on price

Within UK regulated pharmacies, the two medicines are broadly priced in the same range at equivalent dose levels. Specific patterns:

At starter doses

Mounjaro 2.5mg and Wegovy 0.25mg/0.5mg both typically fall in the £130–£190 range. The starter dose is often where promotional discounts are applied, so the gap between providers can be larger than the gap between medicines.

At mid doses

Mounjaro 5mg–10mg and Wegovy 1mg–1.7mg are generally £160–£260 per month. Wegovy at 1.7mg is sometimes priced slightly higher because it is approaching maintenance.

At maintenance dose

Mounjaro 15mg and Wegovy 2.4mg both typically reach £230–£300+ per month. The maintenance-dose pricing is what you'll pay for most of a typical treatment course, so it's the figure that matters most for total cost.

Year 1 total cost comparison

For a typical patient reaching the maintenance dose:

  • Mounjaro 12.5mg long-term: ~£2,850 in year 1 at typical pricing
  • Wegovy 2.4mg long-term: ~£2,760 in year 1 at typical pricing

The difference is typically less than £100 over 12 months — small relative to the cost itself. Choosing on price alone usually means picking the cheaper provider for whichever medicine you're prescribed, not switching medicines purely for cost.

NHS pricing — only the prescription charge

For patients eligible for NHS-funded treatment under NICE TA1026 (Mounjaro) or NICE TA875 (Wegovy):

  • England: standard prescription charge (£9.90 in 2025/26), or free for those who qualify for an exemption
  • Scotland, Wales, Northern Ireland: free at point of dispensing

Annual NHS cost: ~£120 in England; £0 elsewhere. For someone eligible privately at typical pricing, the difference vs NHS is typically £2,500–£3,000 per year.

NHS criteria are tighter than the licensed indication. Eligibility differs between Wegovy (TA875, 2-year cap, accessed through specialist services) and Mounjaro (TA1026, no 2-year cap, accessed in primary care with phased rollout). For details, see our private vs NHS guide.

What drives provider-to-provider variation

Within regulated UK pharmacies, several factors create the pricing range you see across providers:

Wholesale negotiating power

Larger pharmacies with greater purchasing volume can negotiate slightly lower wholesale prices and pass some of the saving through. This is particularly visible at high-street chains (Boots, LloydsDirect) and large online-only pharmacies.

Service model overhead

Online-only providers tend to have lower overheads than high-street chains, often translating to slightly lower retail pricing. High-street providers compete on convenience and integrated healthcare instead of pure price.

Aftercare bundling

A provider charging £20 more per month but including free follow-up consultations may be cheaper overall than a provider charging £20 less but billing for each follow-up. Total cost-of-care matters more than headline price.

Promotional strategy

Some providers run aggressive first-order discounts that revert to standard pricing from month 2 onwards. The headline "month one" price is not always the long-term price.

Subscription vs single-purchase

Some providers offer monthly billing that you can cancel anytime; others require longer commitments at a per-month discount. The latter is cheaper if you stick with it, more expensive if you switch mid-course.

Total cost of treatment — the right number to optimise

The cheapest-this-week pen is the wrong number. The figure that matters is total cost over the time you'll actually be on the medicine.

A reasonable comparison framework:

  • Look at the dose you'll likely settle on long-term, not the starter dose
  • Look at 12 months of pricing, not just month one
  • Factor in aftercare if not bundled
  • Factor in delivery surcharges if you need fast delivery
  • Factor in switching flexibility — some providers require longer commitments

A provider with a steeply discounted starter pen but pricier maintenance often costs more over a year than one with consistent mid-range pricing.

What you should never see

Some pricing patterns are red flags for unregulated supply:

  • Prices dramatically below the regulated UK market — a £40 Mounjaro pen, a £50 Wegovy pen — is a counterfeit-risk signal
  • "No consultation" or "no prescription" needed — unlawful for prescription-only medicines
  • Sale through social media, beauty clinics, "wellness" providers without a regulated pharmacy partner
  • Cash, bank transfer or cryptocurrency only as payment options

The MHRA has warned consumers about these risks. Cheaper than market-rate is rarely actually cheaper once safety, counterfeit risk, and lack of clinical safety net are factored in.

Why retatrutide has no UK price

Retatrutide is not licensed by the MHRA at the time of this guide. No regulated UK pharmacy can supply it. Anyone offering it for sale in the UK is operating outside the regulated supply chain. There is therefore no legitimate UK retail price to compare.

When retatrutide is approved, this site will list regulated UK providers and their prices alongside Mounjaro and Wegovy. Until then:

Pricing comparison — what to do with this information

The practical decisions this hub supports:

Choosing between Mounjaro and Wegovy on price alone

Largely a wash within typical UK pricing. Choose based on clinical fit (efficacy, side effects, eligibility) rather than the £80-per-year difference.

Choosing between two providers for the same medicine

This is where price comparisons matter most. Within regulated UK pharmacies, you can save £30–£50 per month by choosing carefully — meaningful over a year-long treatment.

Choosing between private and NHS

The cost difference (typically £2,500–£3,000 per year) is usually decisive if you meet NHS criteria and can wait. If you don't meet criteria, private is the practical option.

Deciding whether to start vs wait

Pricing has been broadly stable through 2024–2026. There is no clear evidence that significantly cheaper licensed options are about to enter the UK market. Waiting to start is usually a worse option than starting now and switching providers if pricing changes.

Frequently asked questions

Will prices come down significantly?
Probably gradually rather than suddenly. New entrants and biosimilar/generic competition over time will create downward pressure, but neither tirzepatide nor semaglutide is close to going generic in the UK. Substantial price drops are unlikely in the near term.

Are weight-loss injections covered by private medical insurance?
Most UK private medical insurance policies exclude weight-loss medication. Some employer schemes are starting to cover it. Check your policy directly.

Can I save money by ordering 3 or 6 months at once?
Many UK pharmacies offer multi-month bundle pricing at a discount. The trade-off is committing money upfront and being less flexible to switch.

Is the cheapest provider the right choice?
Within regulated UK pharmacies, the right balance is between price, aftercare, and customer service. The cheapest unregulated provider is the worst possible choice — counterfeit risk, no clinical safety net, and potentially dangerous.

Will prices drop when retatrutide launches?
Possibly — increased competition can create downward pressure. But Eli Lilly (which makes both Mounjaro and retatrutide) is unlikely to undercut its own product. Wegovy may face more direct pricing competition than Mounjaro.

Next steps

Sources

This guide is for general information only. Prices change frequently. Always confirm current pricing with the provider before placing an order.

Get weekly weight loss tips

Join our newsletter for provider updates, expert guidance, and exclusive offers — no spam.

Subscribe free
Back to Prices
Weight Loss Injection Price Comparisons UK Hub | LetsLoseWeight